Approved for use through 07/31/2008, OMB 0651-2031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE a collection of information unless it contains a valid OMB control number.

#### Application Number 10811162 Filing Date 2004-03-26 INFORMATION DISCLOSURE First Named Inventor Francisc Sandulescu STATEMENT BY APPLICANT Art Unit 2187 ( Not for submission under 37 CFR 1.99) Examiner Name Emest Unelus Attorney Docket Number NEWT.P0107US

				U.S.	PATENTS		Remove	
Examiner Initial*	Cite No Patent Number		Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Releva	columns,Lines where t Passages or Relevan Appear	
	1	6304895		2001-10-16	Schneider et al.			
	2	6378014		2002-04-23	Shirley			
	3	6539418		2003-03-25	Schneider et al.			
	4	6567869		2003-05-20	Shirley			
	5	6701380		2004-03-02	Schneider et al.			
	6	6782443		2004-08-24	Ferguson			
If you wisl	h to a	dd additional U.S. Pater	t citatio	n information pl	lease click the Add button.	_	Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	er Cite No Publication Number Kind Date Name of Patentee or Applicant of cited Document				Releva	Columns,Lines where nt Passages or Relevant s Appear		

#### 

	1	2002	0038334		2002-0	3-28	Schneider et a	al.					
	2	2003	10135656		2003-07-17		Schneider et al.						
	3	2005	0102437		2005-05-12		Pettey et al.	Pettey et al.					
	4	2006	60039467		2006-0	2-23	Emerson et al.						
If you wish to add additional U.S. Published Application citation information please click the Add button. Add													
					FOREIG	3N PAT	ENT DOCUM	ENT	s		Remove	Ð	
Examiner Initial*	Cite No	Fore	ign Document ber <sup>3</sup>	Country Kind Code <sup>4</sup>		Publication Date Name of Patentee Applicant of cited Document				т			
	1												
If you wis	h to a	dd add	titional Foreign Pa	atent Do	cument	citation	information pl	ease	e click the Add	button	Add		
				NON	I-PATE	NT LITE	RATURE DO	CUN	MENTS		Remove	0	
Examiner Initials*	Cite No								T5				
	1												
If you wis	h to a	dd add	itional non-paten	t literatu	re docu	ment cit	ation informati	ion p	elease click the	Add b	utton A	dd	_
EXAMINER SIGNATURE													
Examiner Signature Date Considered													
*EXAMIN	ER: Ir	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a											

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		10811162	
INFORMATION DIGGI COURT	Filing Date		2004-03-26	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Fran		cisc Sandulescu	
(Not for submission under 37 CFR 1.99)	Art Unit		2187	
(	Examiner Name	Eme	st Unelus	
	Attorney Docket Numb	er	NEWT.P0107US	

See four Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. \* Exister office in all assets for electrons, by the loss letter code (WPO) Standard 51.3. \* \*Projectioned projection pr

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10811162		
Filing Date		2004-03-26		
First Named Inventor	Francisc Sandulescu			
Art Unit		2187		
Examiner Name	Emes	Ernest Unelus		
Attorney Docket Number		NEWT.P0107US		

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate selection(s):
---------------	----------	------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
  - □ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mark C. Johnson/	Date (YYYY-MM-DD)	2006-09-15					
Name/Print	Mark C. Johnson	Registration Number	51.854					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.